Compare Crispr Therapeutics AG (CRSP) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs M&T Bank Corporation — how do they compare? Crispr Therapeutics AG trades at $54.73 (market cap $5.23B), while M&T Bank Corporation trades at $253.01 (market cap $36.42B). The key difference: M&T Bank Corporation is far larger — about 7× Crispr Therapeutics AG's market cap, and M&T Bank Corporation pays a 2.38% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MTB | |
|---|---|---|
Market Cap | $5.23B | $36.42B |
Sector | Health | Financials |
52-Week High | $76.78 | $254.04 |
52-Week Low | $44.34 | $178.63 |
Enterprise Value | $3.65B | — |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
M&T Bank (MTB) trades at $251.13, up 0.27% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows consistent revenue growth, with 2025 revenue at $9.63B and net income margin of 29.59%, supported by a P/E of 13.35. Analyst consensus is a Hold with a $255.92 price target, while recent news highlights robust Q2 2026 results and dividend stability.
Outlook remains positive due to earnings momentum and loan growth, but risks include rising costs and macroeconomic pressures. The stock offers value with a reasonable valuation and dividend yield, though investor caution is warranted amid mixed analyst ratings and net cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
